Dewpoint Therapeutics names new CFO and treasurer
12 February 2021 -

Dewpoint Therapeutics, a United States-based biomolecular condensates company, announced on Thursday that it has named Joel Sendek as its new chief financial officer and treasurer.

Sendek has held the position of CFO at Sema4 and the same position at Spero Therapeutics and at Forward Pharma. He has 17 years of experience as a senior equity research analyst covering biotech and leading healthcare equity research as managing director at Stifel Financial Corp and Lazard. He has served in business development at Progenics Pharmaceuticals and as an investment banker at Goldman Sachs.

Ameet Nathwani, MD, Dewpoint Therapeutics'CEO, said, 'As we accelerate our growth plans, Joel's financial expertise and leadership in fundraising and corporate finance for both private and public biotech companies will be invaluable. I am delighted to welcome him to our rapidly growing team and look forward to the significant contributions he will make as we work to leverage biomolecular condensates to create medicines for some of the world's toughest diseases.'